Kstone Pharma-B (02616.HK) announces the latest progress of the international multicenter phase III study of Nofazinlimab for the treatment of hepatocellular carcinoma.

CapitalMedicines-B (02616.HK) announced the latest progress on the CS1003-305 study. The CS1003-305 study is an international multi-center, double-blind, randomized controlled Phase III registration study with 74 research centers worldwide. It aims to evaluate the efficacy and safety of the PD-1 monoclonal antibody nofazinlimab (CS1003) in combination with lenvatinib compared to placebo in the first-line treatment of unresectable or metastatic hepatocellular carcinoma (HCC) patients. The primary endpoint of the study is overall survival (OS). Key secondary endpoints include progression-free survival (PFS) evaluated by blind independent central review (BICR) and objective response rate (ORR).